盐酸羟考酮缓释片联合氟哌噻吨美利曲辛片治疗晚期癌痛的疗效观察

目的:探讨盐酸羟考酮缓释片联合氟哌噻吨美利曲辛片治疗晚期癌痛的临床疗效。方法:选取80例2013年4月至2015年9月在我院肿瘤内科收治的晚期癌症患者，随机分为观察组和对照组，均为40例。观察组联合使用盐酸羟考酮缓释片和氟哌噻吨美利曲辛片，对照组仅单用盐酸羟考酮缓释片。1个月后对两组患者治疗过程中记录的疼痛程度分级、抑郁量表评分、药物使用剂量以及不良反应进行整理分析，综合比较两组的临床疗效。结果:治疗前两组NRS评分无显著性差异（P＞0.05），治疗后两组NRS评分均显著降低（P＜0.05）；且与对照组相比，观察组NRS评分降低幅度更大；与之类似，治疗前两组患者抑郁量表评分无显著性差异（P＞0.05），治疗后观察组与对照组的SDS和HRSD评分均显著降低（P＜0.05），同时观察组比对照组评分降低更显著（P＜0.05）；观察组人均日剂量为（45.62±5.17） mg/d,对照组人均日剂量为（62.18±4.37） mg/d，观察组显著低于对照组；但不良反应发生率方面，观察组与对照组并无显著性差异（P＞0.05）。结论:在盐酸羟考酮缓释片的基础上联合使用氟哌噻吨美利曲辛片对晚期癌痛患者的疗效确切，能够进一步改善癌痛患者的焦虑抑郁，并且可以降低盐酸羟考酮缓释片的使用剂量，值得推广应用。

The clinical efficacy observation of oxycodone hydrochloride prolonged-release tablets combined with flupentixol and melitracentablets for terminal cancer-induced pain

Objective:To evaluate the clinical efficacy of oxycodone hydrochloride prolonged-release tablets combined with flupentixol and melitracen tablets for advanced cancer-induced pain.Methods:We selected 80 cases of advanced cancer patients treated in our hospital from April 2013 to September 2015,they were randomly divided into observation group and control group,40 cases in each group.Patients in observation group received a combination of oxycodone hydrochloride prolonged-release tablets and flupentixol and melitracen tablets,patients in control group only received oxycodone hydrochloride prolonged-release tablets.After 1 months,the records of the two groups' degree of pain depression scale score,drug use dose and adverse reactions in the course of treatment were colleted and analyzed,comprehensively compared the clinical efficacy of the medicine in two groups.Results:There was no significant difference in NRS scores between the two groups before treatment (P>0.05).The scores of NRS in the two groups were significantly after decreased after treatment (P＜0.05),and compared with the control group,the NRS score of the observation group decreased more significantly.Similarly,the depression scale scores in two groups before treatment had no significant difference (P>0.05).After treatment,both the observation group and the control group of SDS and HRSD scores were significantly decreased (P＜0.05),what's more,the observation group decreased more significantly than the control group(P＜0.05),the average daily dose of the observation group is （45.62±5.17）mg/d,and the control group was (62.18±4.37) mg/d,the observation group was significantly lower than the control group(P＜ 0.05),but in the aspect of the incidence of adverse reactions,there is no significant difference between the two groups(P>0.05).Conclusion:The clinical efficacy of oxycodone hydrochloride prolonged-release tablets combined with flupentixol and melitracen tablets for terminal cancer-induced pain is significant.It can further lighten the pain in patients with anxiety and depression,and can reduce the dose of oxycodone hydrochloride prolonged-release tablets,it is worthy of popularization and application.